NIMRA 1000mg coated granules in sachet medication leaflet

B02AA02 tranexamic acid • Blood and blood forming organs | Antifibrinolytics | Amino acids

Tranexamic acid is an antifibrinolytic agent used to prevent and treat excessive bleeding caused by increased fibrinolysis, a process in which blood clots dissolve too quickly. It works by inhibiting plasminogen, thereby reducing fibrin degradation and helping to stabilize blood clots.

It is used for the treatment of heavy menstrual bleeding (menorrhagia), postoperative hemorrhages, severe trauma, and hemophilia. It is also administered in postpartum hemorrhage to reduce the risk of severe complications.

Tranexamic acid can be given orally, intravenously, or topically, depending on the medical indication. It is preferred for its relatively high safety profile and effectiveness in reducing blood loss without significantly increasing the risk of thrombosis.

Side effects include nausea, diarrhea, headache, and, in rare cases, severe allergic reactions or thrombotic events. It is not recommended for patients with a history of thromboembolism without close medical supervision.

General data about NIMRA 1000mg

Substance: tranexamic acid

Date of last drug list: 01-03-2026

Commercial code: W71694001

Concentration: 1000mg

Pharmaceutical form: coated granules in sachet

Quantity: 12

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: INPHARMASCI - FRANTA

Holder: CEMAG CARE - FRANTA

Number: 16422/2026/01

Shelf life: 3 years

Concentrations available for tranexamic acid

0.5g/5ml, 1000mg, 100mg/ml, 10mg/ml, 500mg, 500mg/5ml